Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)
255.76 -14.26 (-5.28%) 04/01/25 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime 257.19 +1.43 (+0.56%) 19:05 ET
Quote Overview for Tue, Apr 1st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
255.13
Day High
273.61
Open 272.52
Previous Close 270.02 270.02
Volume 868,300 868,300
Avg Vol 916,515 916,515
Stochastic %K 43.63% 43.63%
Weighted Alpha +26.99 +26.99
5-Day Change -25.20 (-8.97%) -25.20 (-8.97%)
52-Week Range 141.98 - 304.39 141.98 - 304.39
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 35,125,552
  • Shares Outstanding, K 130,085
  • Annual Sales, $ 2,248 M
  • Annual Income, $ -278,160 K
  • EBIT $ -177 M
  • EBITDA $ -120 M
  • 60-Month Beta 0.39
  • Price/Sales 15.53
  • Price/Cash Flow N/A
  • Price/Book 516.13

Options Overview Details

View History
  • Implied Volatility 40.92% ( +0.64%)
  • Historical Volatility 50.76%
  • IV Percentile 52%
  • IV Rank 7.96%
  • IV High 149.76% on 06/21/24
  • IV Low 31.51% on 01/23/25
  • Put/Call Vol Ratio 1.88
  • Today's Volume 484
  • Volume Avg (30-Day) 1,356
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 21,805
  • Open Int (30-Day) 18,736

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.94
  • Number of Estimates 12
  • High Estimate -0.04
  • Low Estimate -1.51
  • Prior Year -0.52
  • Growth Rate Est. (year over year) -80.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
230.79 +10.82%
on 03/11/25
Period Open: 246.75
300.90 -15.00%
on 03/24/25
+9.01 (+3.65%)
since 02/28/25
3-Month
230.79 +10.82%
on 03/11/25
Period Open: 235.31
300.90 -15.00%
on 03/24/25
+20.45 (+8.69%)
since 12/31/24
52-Week
141.98 +80.14%
on 04/25/24
Period Open: 153.33
304.39 -15.98%
on 10/17/24
+102.43 (+66.80%)
since 04/01/24

Most Recent Stories

More News
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States

Sanofi SNY and partner, Alnylam Pharmaceuticals ALNY, announced that the FDA has approved Qfitlia (fitusiran) as the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce...

BAYRY : 6.0500 (+0.50%)
CORT : 91.93 (-19.51%)
ALNY : 255.76 (-5.28%)
SNY : 54.34 (-2.02%)
Incyte Stock: Is INCY Outperforming the Health Care Sector?

Incyte has outperformed the health care sector over the past year, and analysts are moderately optimistic about the stock’s prospects.

XLV : 143.34 (-1.83%)
ALNY : 255.76 (-5.28%)
INCY : 60.91 (+0.59%)
Stocks Recover Early Losses and Close Higher as Magnificent Seven Stocks Rebound

The S&P 500 Index ($SPX ) (SPY ) Friday closed up +0.08%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.08%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.39%. June E-mini S&P futures...

GOOGL : 157.07 (+1.57%)
AMAT : 145.66 (+0.37%)
AAPL : 223.19 (+0.48%)
DHI : 127.41 (+0.22%)
$IUXX : 19,436.42 (+0.82%)
ASML : 667.34 (+0.71%)
ZNM25 : 111-210 (-0.11%)
MSFT : 382.19 (+1.81%)
TSLA : 268.46 (+3.59%)
ESM25 : 5,664.50 (-0.18%)
PHM : 103.04 (+0.23%)
NCLH : 19.06 (+0.53%)
Stocks Pare Losses as S&P 500 Looks for Weekly Win

The S&P 500 Index ($SPX ) (SPY ) today is down -0.31%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.20%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.18%. June E-mini S&P futures...

AMAT : 145.66 (+0.37%)
TAP : 61.24 (+0.61%)
DHI : 127.41 (+0.22%)
KHC : 30.34 (-0.30%)
TXN : 177.99 (-0.95%)
$IUXX : 19,436.42 (+0.82%)
ASML : 667.34 (+0.71%)
ZNM25 : 111-210 (-0.11%)
HLT : 227.28 (-0.12%)
ESM25 : 5,664.50 (-0.18%)
PHM : 103.04 (+0.23%)
GFS : 35.98 (-2.52%)
Weak Corporate Earnings Results Weigh on Stocks

The S&P 500 Index ($SPX ) (SPY ) today is down -0.81%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.95%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.97%. March E-mini S&P futures...

AMAT : 145.66 (+0.37%)
UAL : 68.20 (-1.23%)
TAP : 61.24 (+0.61%)
KHC : 30.34 (-0.30%)
$IUXX : 19,436.42 (+0.82%)
ASML : 667.34 (+0.71%)
ZNM25 : 111-210 (-0.11%)
HLT : 227.28 (-0.12%)
ESM25 : 5,664.50 (-0.18%)
GFS : 35.98 (-2.52%)
QCOM : 153.05 (-0.36%)
NCLH : 19.06 (+0.53%)
Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum?

Alnylam Pharmaceuticals ALNY focuses on developing novel therapeutics based on RNAi technology. The company’s pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic...

ALNY : 255.76 (-5.28%)
NVS : 109.61 (-1.68%)
REGN : 617.00 (-2.72%)
RHHBY : 41.0800 (-0.17%)
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag

Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application (sBLA) seeking approval for Dupixent for treating bullous pemphigoid (BP), a chronic,...

ALNY : 255.76 (-5.28%)
GILD : 111.28 (-0.69%)
REGN : 617.00 (-2.72%)
SNY : 54.34 (-2.02%)
Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y

Alnylam Pharmaceuticals ALNY reported fourth-quarter 2024 adjusted earnings of 6 cents per share, in contrast with the Zacks Consensus Estimate of a loss of 21 cents. The company had incurred a loss of...

ALNY : 255.76 (-5.28%)
NVS : 109.61 (-1.68%)
REGN : 617.00 (-2.72%)
RHHBY : 41.0800 (-0.17%)
Alnylam Delivers a Big Q4 Earnings Beat

Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.

ALNY : 255.76 (-5.28%)
NVS : 109.61 (-1.68%)
Alnylam: Q4 Earnings Snapshot

Alnylam: Q4 Earnings Snapshot

ALNY : 255.76 (-5.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic...

See More

Key Turning Points

3rd Resistance Point 286.34
2nd Resistance Point 279.97
1st Resistance Point 267.87
Last Price 255.76
1st Support Level 249.39
2nd Support Level 243.02
3rd Support Level 230.92

See More

52-Week High 304.39
Last Price 255.76
Fibonacci 61.8% 242.35
Fibonacci 50% 223.18
Fibonacci 38.2% 204.02
52-Week Low 141.98

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies